Flipside Finance
PF

Pfizer Inc.

PFEEquity
$26.04+0.15%
24h Volume: $0.03B

AI Summary

Updated 6h ago

Pfizer Inc

Pfizer Inc. (PFE) is in an unusual state of calm. Volatility is near historic lows — quieter than it has been at almost any point in recent memory. This kind of compression tends to precede a significant move, though it offers no indication of direction. For reference: Flow Score 48/100, Trend & Momentum Score 50/100.

55Neutral
Market position

Market Positioning

36Below avg
Extension
63Above avg
Momentum
66Above avg
Flow
3Quiet
Volatility

What's Happening

Updated 3d ago

Pfizer locks in 2026 guidance and cost-reset targets

On 2026-05-29, Pfizer reaffirmed full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and EPS guidance of $2.80 to $3.00, while also calling for operational revenue growth of about 4% at the midpoint excluding COVID-19 and LOE products. The detail that matters is the margin bridge — Pfizer is pairing top-line stabilization with $23.0 billion to $25.0 billion in combined adjusted SI&A and R&D spending, which signals the company is still leaning hard on its cost realignment program to defend earnings power.

The Bigger Picture

Updated 3d ago
Pfizer is in a post-COVID reset, not a growth story yet
Guidance now matters more than headlines

Pfizer’s 2026 guide is framed around $59.5 billion to $62.5 billion of revenue and $2.80 to $3.00 of adjusted EPS, so the market is watching execution rather than narrative. The key question is whether Pfizer can hold its margin structure while it absorbs COVID normalization and LOE pressure. That makes every incremental change in cost discipline more important than the headline revenue number.

Flow Score: 47/100Trend Score: 51/1003-Month Return: -1.4%

Upcoming Catalysts

Updated 3d ago
Late July 2026Pre-earnings investor updates

Pfizer often uses the weeks before earnings to reinforce guidance and shape expectations through investor communications and conference appearances. Any update that clarifies the pace of operational revenue growth or expense control could matter more than the headline itself. [6][4]

Aug 4Q2 2026 earnings

Pfizer is widely expected to report around this date based on market calendars. Investors will focus on whether the company keeps validating its 2026 revenue and EPS guide and whether cost realignment is continuing to support margins. [3][1]

Next 90 daysFollow-through on 2026 guidance

Investors will watch for any management commentary that confirms the full-year revenue range of $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3.00. The key issue is whether Pfizer can hold that frame without further reliance on one-off support from legacy product trends. [1]

Positive Catalyst
Earnings

Technical Analysis

Market Positioning

Where does this asset sit across four dimensions? Extension (how stretched price is vs its own history), Momentum (RSI, MACD, rate of change), Flow (volume and money flow), and Volatility (how quiet or active). Each bar shows a 0–100 percentile compared to the last year of data. Key levels show the nearest demand and supply zones from our confluence analysis.

Extension
[avg: 36th]
36thpercentile
Low
Normal
High
36th percentile
Momentum
[avg: 63rd]
63rdpercentile
Low
Normal
High
63rd percentile
Flow
[avg: 66th]
66thpercentile
Low
Normal
High
66th percentile
Volatility
[avg: 3rd]
3rdpercentile
Low
Normal
High
3rd percentile

Key Levels

Demand: $23–$28 (0.7% below)
score: 30.54
Supply: $29–$29 (10.7% above)
score: 3.24
View full Key Levels section →

Looking at the full picture for Pfizer Inc. (PFE): extension is slightly below average (36th percentile), momentum is slightly above average (63rd percentile), flow is slightly above average (66th percentile), volatility is deeply below average — at historically low levels (3rd percentile). The standout feature is the volatility compression — the asset is unusually quiet relative to its own history. This kind of compression often precedes a significant move. The directional indicators are not extreme in either direction, which makes the volatility reading the most notable signal right now. Volatility compression at these levels rarely persists for long. A move above or below the recent range with rising volume would signal that the compression is resolving.

Conclusion

The most notable thing about Pfizer Inc. (PFE) right now is the volatility compression — the asset is unusually quiet. Volatility rarely stays this low for long, and a significant move is likely building. There is not a strong signal here in either direction. This is an asset to watch rather than act on right now. A break above or below the recent range with rising volume would be the signal that the compression is resolving. These readings update daily. Flipside shows what is happening now, grounded in the data — not what will happen next.

Your portfolio. Your context. Smarter decisions.

Connect your holdings and let the Flipside Agent analyze market changes through the lens of your portfolio.

AI + Portfolio

Personalized insights based on your actual holdings

Daily Briefing

Major market movements delivered to your inbox

Watchlists

Track the assets that matter most to you

Create your free account

No credit card required